Serum Institute of India has new results from a phase 3 trial of its rotavirus vaccine as it preps to deliver millions of doses.
Following a rush of news coverage into an unregulated human trial of a herpes vaccine in St. Kitts, the island’s government is launching a probe.
Three major regulatory bodies – FDA, EMA and Health Canada – changed their guidelines to drug naming. How could these changes impact drug launch timelines?
As part of a crackdown on stem cell clinics, the FDA found an operation using Sanofi's smallpox vaccine in an illegitimate cancer therapy.
An American university and a group of wealthy libertarians, including Peter Thiel, are backing the offshore testing of an experimental herpes vaccine.
MSF's strong opposition didn't stop India's government from granting Pfizer a patent that protects Prevnar's exclusivity till 2026.
Make no mistake: FDA Commissioner Scott Gottlieb does not want to be associated with the anti-vaxxer movement.
The FDA is asking for more details about Heplisav-B's postmarketing surveillance plan, but Dynavax executives and analysts said they remain confident.
For three of the world’s top four vaccine companies, sales growth churned along in the second quarter as other areas struggled.
At Dynavax’s third try, an FDA panel favored hepatitis B candidate Heplisav-B's safety profile by a vote of 12 to 1.
While GSK is still expected to top the vaccine industry in 2022, rankings for other players have shifted in Evaluate's new World Preview.